CMS needs to improve its oversight of Medicare Part B drugs’ average sales prices (ASPs) to ensure that providers are being correctly reimbursed and patients aren’t overcharged, the HHS Office of the Inspector General (HHS OIG) says. Ensuring the accuracy of ASPs is vital because CMS uses these prices to directly calculate payment amounts under Medicare Part B. Inaccurate ASPs can increase costs for Medicare and patients, or create drug access issues if providers are paid below cost, the HHS...